These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38334994)

  • 1. Medicare Part D Coverage of Drugs Selected for the Drug Price Negotiation Program.
    Patterson JA; Wagner TD; O'Brien JM; Campbell JD
    JAMA Health Forum; 2024 Feb; 5(2):e235237. PubMed ID: 38334994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
    Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
    JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017.
    Hwang TJ; Dusetzina SB; Feng J; Maini L; Kesselheim AS
    JAMA; 2019 Jul; 322(3):267-269. PubMed ID: 31310287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial hardship from purchasing prescription drugs among older adults in the United States before, during, and after the Medicare Part D "Donut Hole": Findings from 1998, 2001, 2015, and 2021.
    Olson AW; Schommer JC; Mott DA; Adekunle O; Brown LM
    J Manag Care Spec Pharm; 2022 May; 28(5):508-517. PubMed ID: 35471065
    [No Abstract]   [Full Text] [Related]  

  • 9. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
    Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
    J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of Medicare prescription drug coverage on the use of antidementia drugs.
    Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM
    BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs likely subject to Medicare negotiation, 2026-2028.
    Dickson S; Hernandez I
    J Manag Care Spec Pharm; 2023 Mar; 29(3):229-235. PubMed ID: 36840960
    [No Abstract]   [Full Text] [Related]  

  • 15. Demand for prescription drugs under non-linear pricing in Medicare Part D.
    Jung K; Feldman R; McBean AM
    Int J Health Care Finance Econ; 2014 Mar; 14(1):19-40. PubMed ID: 24214101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug coverage and chronic pain.
    Ayyagari P
    Int J Health Econ Manag; 2016 Jun; 16(2):189-200. PubMed ID: 27878715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The January effect: medication reinitiation among Medicare Part D beneficiaries.
    Kaplan C; Zhang Y
    Health Econ; 2014 Nov; 23(11):1287-300. PubMed ID: 23943539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
    Johnson M; Kishore S; Nayak RK; Dusetzina SB
    Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical advertising and Medicare Part D.
    Lakdawalla D; Sood N; Gu Q
    J Health Econ; 2013 Dec; 32(6):1356-67. PubMed ID: 24308884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare program: Medicare Advantage and prescription drug programs MIPPA drug formulary & protected classes policies. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2009 Jan; 74(11):2881-8. PubMed ID: 19385109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.